Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O
Incannex Healthcare Limited recently announced it has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture Incannex’s two distinct medicated….
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
Daré Bioscience, Inc. recently announced it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to...IMUNON Enters Technology Evaluation Agreement With Acuitas to Evaluate Placcine Plasmid DNA With Lipid Nanoparticle Delivery System
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA and protein vaccines….
Evonik Wins Pharma Award for Polymer-Based Technology for mRNA Delivery
Evonik Health Care has won the prestigious CPHI Excellence in Pharma Award in the category Packaging and Drug Delivery. The...FORMULATION FORUM - Lipid Nanoparticles: Tackling Solubility Challenges With Lipid-Based Technologies for Oral & Injectable Formulations
Jim Huang, PhD, and Shaukat Ali, PhD, believe as more hydrophobic or brick dust and/or lipophilic or waxy molecules come out of discovery, amorphous solid dispersions (ASDs) and lipid based self-emulsifying microemulsions, nanoemulsions, liposomes, and nanoparticles are ideal for oral and injectable formulations.
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
Silo Pharma, Inc. recently announced it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated as….
PLATFORM TECHNOLOGY - The Evolution of Cancer Vaccines: Moving Beyond Failure & a New Era for Cancer Treatment
Jeremy R. Graff, PhD, says new studies show promising data with the use of mRNA-based vaccines and the injection of nanoparticles into regional lymph nodes to achieve disease stabilization. This has led to a potentially groundbreaking era of therapeutic cancer vaccines thanks to discoveries in identifying truncal targets, targeting tumor neoantigens and, notably, developing improved delivery technologies that stimulate a robust, targeted, and persistent immune response.
SPECIAL FEATURE - Injection Devices: Three Trends Influencing Development & Delivery
Contributor Cindy H. Dubin showcases in this annual feature how various innovative device manufacturers are addressing the current trends in their injection designs.
Daré Bioscience Announces Global Licensing Rights to Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
Daré Bioscience, Inc. recently announced it has entered into a license agreement with Hennepin Life Sciences LLC under which Daré...Xequel Bio Announces Positive Results From Phase 1b Study for Novel aCT1 Ophthalmic Solution
Xequel Bio, Inc. recently announced positive results from its Phase 1b clinical trial with iNexin (aCT1 ophthalmic solution) for the...
